IRIS Accounts Production v25.4.0.155 01818053 Board of Directors 1.4.24 31.3.25 31.3.25 true false true true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh018180532024-03-31018180532025-03-31018180532024-04-012025-03-31018180532022-09-30018180532022-10-012024-03-31018180532024-03-3101818053ns15:EnglandWales2024-04-012025-03-3101818053ns14:PoundSterling2024-04-012025-03-3101818053ns10:Director12024-04-012025-03-3101818053ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3101818053ns10:MediumEntities2024-04-012025-03-3101818053ns10:Audited2024-04-012025-03-3101818053ns10:Medium-sizedCompaniesRegimeForAccounts2024-04-012025-03-3101818053ns10:FullAccounts2024-04-012025-03-310181805312024-04-012025-03-3101818053ns10:OrdinaryShareClass12024-04-012025-03-3101818053ns10:Director22024-04-012025-03-3101818053ns10:RegisteredOffice2024-04-012025-03-3101818053ns5:CurrentFinancialInstruments2025-03-3101818053ns5:CurrentFinancialInstruments2024-03-3101818053ns5:Non-currentFinancialInstruments2025-03-3101818053ns5:Non-currentFinancialInstruments2024-03-3101818053ns5:ShareCapital2025-03-3101818053ns5:ShareCapital2024-03-3101818053ns5:RetainedEarningsAccumulatedLosses2025-03-3101818053ns5:RetainedEarningsAccumulatedLosses2024-03-3101818053ns5:ShareCapital2022-09-3001818053ns5:RetainedEarningsAccumulatedLosses2022-09-3001818053ns5:RetainedEarningsAccumulatedLosses2022-10-012024-03-3101818053ns5:RetainedEarningsAccumulatedLosses2024-04-012025-03-310181805312024-04-012025-03-310181805312022-10-012024-03-310181805322024-04-012025-03-310181805322022-10-012024-03-3101818053ns5:NetGoodwill2024-04-012025-03-3101818053ns5:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3101818053ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-04-012025-03-3101818053ns5:FurnitureFittings2024-04-012025-03-3101818053ns5:MotorVehicles2024-04-012025-03-3101818053ns5:ComputerEquipment2024-04-012025-03-3101818053ns5:OwnedAssets2024-04-012025-03-3101818053ns5:OwnedAssets2022-10-012024-03-3101818053ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2022-10-012024-03-3101818053ns5:HirePurchaseContracts2024-04-012025-03-3101818053ns5:HirePurchaseContracts2022-10-012024-03-3101818053ns10:OrdinaryShareClass12022-10-012024-03-3101818053ns5:NetGoodwill2024-03-3101818053ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-03-3101818053ns5:NetGoodwill2025-03-3101818053ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-03-3101818053ns5:NetGoodwill2024-03-3101818053ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-03-3101818053ns5:LandBuildingsns5:ShortLeaseholdAssets2024-03-3101818053ns5:LeaseholdImprovements2024-03-3101818053ns5:FurnitureFittings2024-03-3101818053ns5:LandBuildingsns5:ShortLeaseholdAssets2024-04-012025-03-3101818053ns5:LeaseholdImprovements2024-04-012025-03-3101818053ns5:LandBuildingsns5:ShortLeaseholdAssets2025-03-3101818053ns5:LeaseholdImprovements2025-03-3101818053ns5:FurnitureFittings2025-03-3101818053ns5:LandBuildingsns5:ShortLeaseholdAssets2024-03-3101818053ns5:LeaseholdImprovements2024-03-3101818053ns5:FurnitureFittings2024-03-3101818053ns5:MotorVehicles2024-03-3101818053ns5:ComputerEquipment2024-03-3101818053ns5:MotorVehicles2025-03-3101818053ns5:ComputerEquipment2025-03-3101818053ns5:MotorVehicles2024-03-3101818053ns5:ComputerEquipment2024-03-3101818053ns5:CostValuation2024-03-3101818053ns5:Subsidiary12024-04-012025-03-31018180531ns5:Subsidiary12024-04-012025-03-3101818053ns5:Subsidiary12025-03-3101818053ns5:Subsidiary12024-03-3101818053ns5:Subsidiary12024-03-3101818053ns5:Subsidiary12022-10-012024-03-3101818053ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3101818053ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3101818053ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2025-03-3101818053ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2024-03-3101818053ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2025-03-3101818053ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2024-03-3101818053ns5:HirePurchaseContracts2025-03-3101818053ns5:HirePurchaseContracts2024-03-3101818053ns5:WithinOneYear2025-03-3101818053ns5:WithinOneYear2024-03-3101818053ns5:BetweenOneFiveYears2025-03-3101818053ns5:BetweenOneFiveYears2024-03-3101818053ns5:MoreThanFiveYears2025-03-3101818053ns5:MoreThanFiveYears2024-03-3101818053ns5:AllPeriods2025-03-3101818053ns5:AllPeriods2024-03-3101818053ns5:DeferredTaxation2024-03-3101818053ns5:DeferredTaxation2024-04-012025-03-3101818053ns5:DeferredTaxation2025-03-3101818053ns10:OrdinaryShareClass12025-03-3101818053ns5:RetainedEarningsAccumulatedLosses2024-03-31
REGISTERED NUMBER: 01818053 (England and Wales)












HYPERCHEM LIMITED

REPORT OF THE DIRECTORS AND

AUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025






HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025










Page

Company Information 1

Report of the Directors 2

Report of the Independent Auditors 4

Income Statement 8

Other Comprehensive Income 9

Statement of Financial Position 10

Statement of Changes in Equity 11

Statement of Cash Flows 12

Notes to the Statement of Cash Flows 13

Notes to the Financial Statements 14


HYPERCHEM LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2025







DIRECTORS: Mrs V S Patel
Mr S H Patel



REGISTERED OFFICE: Sterling House
Fulbourne Road
Walthamstow
London
E17 4EE



REGISTERED NUMBER: 01818053 (England and Wales)



SENIOR STATUTORY AUDITOR: Antony Kounnis FCCA



AUDITORS: Christiansons Ltd
Chartered Certified Accountants
& Statutory Auditors
Sterling House
Fulbourne Road
Walthamstow
London
E17 4EE

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 31 MARCH 2025


The directors present their report with the financial statements of the company for the year ended 31 March 2025.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of running retail pharmacies.

REVIEW OF BUSINESS
The results for the year and financial position of the company are as shown in the annexed financial statements.

DIVIDENDS
No interim dividend was paid during the year. The directors recommend a final dividend of £250 per share.

The total distribution of dividends for the year ended 31 March 2025 will be £ 500,000 .

DIRECTORS
The directors shown below have held office during the whole of the period from 1 April 2024 to the date of this report.

Mrs V S Patel
Mr S H Patel

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 31 MARCH 2025


AUDITORS
The auditors, Christiansons Ltd, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:



Mr S H Patel - Director


15 December 2025

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
HYPERCHEM LIMITED


Opinion
We have audited the financial statements of Hyperchem Limited (the 'company') for the year ended 31 March 2025 which comprise the Income Statement, Other Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flows and Notes to the Statement of Cash Flows, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 March 2025 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Directors has been prepared in accordance with applicable legal requirements.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
HYPERCHEM LIMITED


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to take advantage of the small companies' exemption from the requirement to prepare a Strategic Report.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page two, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
HYPERCHEM LIMITED


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, represent instances of non-compliance with laws and regulations. We implement procedures aligned with our responsibilities, as outlined above, to detect material misstatements related to irregularities, including fraud. The effectiveness of our procedures in identifying such irregularities are detailed below.

We considered the nature of the company's industry and its control environment, and we reviewed the company's policies and procedures concerning fraud and compliance with laws and regulations. Additionally, we consulted with management about their own identification and assessment of the risks associated with irregularities.

We gained an understanding of the legal and regulatory framework in which the company operates, identifying key laws and regulations that:

1. Have a direct effect on the determination of material amounts and disclosures in the financial
statements, such as the UK Companies Act, pensions legislation, and tax legislation.
2. Do not directly affect the financial statements but are fundamental to the company's ability to operate or to avoid significant penalties, such as regulatory solvency requirements and environmental regulations.

We also discussed with the audit engagement team, including relevant internal specialists such as those in tax, valuations, pensions, and IT, about the opportunities and incentives for fraud that may exist within the organization and how and where fraud could occur in the financial statements.

Because of the discussion, we identified the following high risk areas with the potential of significant high fraud risk. We have also described below our procedures to address these risk:

1. Revenue recognition, NHS sales have been tested with counter sales and also NHS statements, 3rd party statements, have been reconciled to the bank receipts and with the accounting system to ensure that NHS revenue completely recognised into the account.

2. As a norm for audits under ISAs (UK), we are also required to perform audit procedures to respond to the risk of management override. We responded by testing the appropriateness of the journal entries and other estimates in the financial statements, considering their potential bias and evaluated the business rational of significant transactions that are unusual or outside the normal course of the business.

We have also reviewed, the disclosures by testing the supporting documentation to assess the compliance with relevant laws and regulations which have a direct effect on the financial statements.

We have also performed analytical reviews alongside management enquiry to indemnify potential litigations or claims, and instance of non compliance with the laws and regulation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
HYPERCHEM LIMITED


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Antony Kounnis FCCA (Senior Statutory Auditor)
for and on behalf of Christiansons Ltd
Chartered Certified Accountants
& Statutory Auditors
Sterling House
Fulbourne Road
Walthamstow
London
E17 4EE

15 December 2025

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

INCOME STATEMENT
FOR THE YEAR ENDED 31 MARCH 2025

Period
1.10.22
Year Ended to
31.3.25 31.3.24
Notes £    £   

REVENUE 8,592,600 12,603,021

Cost of sales 5,881,594 8,647,188
GROSS PROFIT 2,711,006 3,955,833

Administrative expenses 2,557,383 3,487,933
153,623 467,900

Other operating income - 3,210
OPERATING PROFIT 4 153,623 471,110

Interest receivable and similar income 266 178
153,889 471,288

Interest payable and similar expenses 5 21,823 3,242
PROFIT BEFORE TAXATION 132,066 468,046

Tax on profit 6 37,755 127,408
PROFIT FOR THE FINANCIAL YEAR 94,311 340,638

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2025

Period
1.10.22
Year Ended to
31.3.25 31.3.24
Notes £    £   

PROFIT FOR THE YEAR 94,311 340,638


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

94,311

340,638

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

STATEMENT OF FINANCIAL POSITION
31 MARCH 2025

31.3.25 31.3.24
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 8 - 10,960
Property, plant and equipment 9 897,823 450,403
Investments 10 1,000 1,000
898,823 462,363

CURRENT ASSETS
Inventories 11 799,417 625,755
Debtors 12 2,505,658 2,655,579
Cash at bank and in hand 175,020 216,130
3,480,095 3,497,464
CREDITORS
Amounts falling due within one year 13 2,179,144 1,321,883
NET CURRENT ASSETS 1,300,951 2,175,581
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,199,774

2,637,944

CREDITORS
Amounts falling due after more than one year 14 (16,632 ) (41,639 )

PROVISIONS FOR LIABILITIES 16 (17,758 ) (25,232 )
NET ASSETS 2,165,384 2,571,073

CAPITAL AND RESERVES
Called up share capital 17 2,000 2,000
Retained earnings 18 2,163,384 2,569,073
SHAREHOLDERS' FUNDS 2,165,384 2,571,073

The financial statements were approved by the Board of Directors and authorised for issue on 15 December 2025 and were signed on its behalf by:





Mr S H Patel - Director


HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025

Called up
share Retained Total
capital earnings equity
£    £    £   
Balance at 1 October 2022 2,000 2,478,435 2,480,435

Changes in equity
Dividends - (250,000 ) (250,000 )
Total comprehensive income - 340,638 340,638
Balance at 31 March 2024 2,000 2,569,073 2,571,073

Changes in equity
Dividends - (500,000 ) (500,000 )
Total comprehensive income - 94,311 94,311
Balance at 31 March 2025 2,000 2,163,384 2,165,384

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2025

Period
1.10.22
Year Ended to
31.3.25 31.3.24
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 64,155 249,866
Interest paid (21,823 ) (2,064 )
Interest element of hire purchase payments
paid

-

(1,178

)
Tax paid (114,889 ) 64,465
Net cash from operating activities (72,557 ) 311,089

Cash flows from investing activities
Purchase of tangible fixed assets (572,281 ) (85,283 )
Interest received 266 178
Net cash from investing activities (572,015 ) (85,105 )

Cash flows from financing activities
Capital repayments in year (25,043 ) 66,622
Group undertakings balances 1,158,505 (22,802 )
Group undertakings balances (30,000 ) 66
Equity dividends paid (500,000 ) (250,000 )
Net cash from financing activities 603,462 (206,114 )

(Decrease)/increase in cash and cash equivalents (41,110 ) 19,870
Cash and cash equivalents at beginning of
year

2

216,130

196,260

Cash and cash equivalents at end of year 2 175,020 216,130

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

NOTES TO THE STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2025


1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM
OPERATIONS

Period
1.10.22
Year Ended to
31.3.25 31.3.24
£    £   
Profit before taxation 132,066 468,046
Depreciation charges 135,821 200,134
Finance costs 21,823 3,242
Finance income (266 ) (178 )
289,444 671,244
Increase in inventories (173,662 ) (66,913 )
Increase in trade and other debtors (6,277 ) (461,435 )
(Decrease)/increase in trade and other creditors (45,350 ) 106,970
Cash generated from operations 64,155 249,866

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Statement of Cash Flows in respect of cash and cash equivalents are in respect of these Statement of Financial Position amounts:

Year ended 31 March 2025
31.3.25 1.4.24
£    £   
Cash and cash equivalents 175,020 216,130
Period ended 31 March 2024
31.3.24 1.10.22
£    £   
Cash and cash equivalents 216,130 196,260


3. ANALYSIS OF CHANGES IN NET FUNDS

At 1.4.24 Cash flow At 31.3.25
£    £    £   
Net cash
Cash at bank and in hand 216,130 (41,110 ) 175,020
216,130 (41,110 ) 175,020
Debt
Finance leases (66,622 ) 25,043 (41,579 )
(66,622 ) 25,043 (41,579 )
Total 149,508 (16,067 ) 133,441

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025


1. STATUTORY INFORMATION

Hyperchem Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to the profit and loss account as incurred.

Turnover
Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill consists of the amount paid in connection with the acquisition of a business in 2008, amortised evenly over its useful economic life of 10 years together with the amount paid in connection with the aquisition of business in 2011 and in 2014 amortised evenly over its estimated useful life of five years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Development costs are being amortised evenly over their estimated useful life of nil years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 20% on reducing balance
Motor vehicles - 25% on reducing balance
Computer equipment - 33% on cost

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Stocks
Inventories are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.


HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Significant judgements and estimates
The preparation of the group undertakings financial statements requires management to make judgements, estimates and assumption that affect the reported amounts of revenue, expenses, assets and liabilities and the disclosures at the reporting period end date. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

However, uncertainty about these assumptions and estimates could result in outcomes that requires and material adjustment to the carrying amount of the asset or liability affected in to the further periods.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, on in the period of the revision and future periods if the revision affects both current and future periods.

3. EMPLOYEES AND DIRECTORS
Period
1.10.22
Year Ended to
31.3.25 31.3.24
£    £   
Wages and salaries 1,221,340 1,828,312
Social security costs 107,671 155,958
Other pension costs 17,022 24,980
1,346,033 2,009,250

The average number of employees during the year was as follows:
Period
1.10.22
Year Ended to
31.3.25 31.3.24

Administrative staff 6 6
Pharmacies staff 43 47
49 53

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


3. EMPLOYEES AND DIRECTORS - continued

Period
1.10.22
Year Ended to
31.3.25 31.3.24
£    £   
Directors' remuneration 11,576 29,859

4. OPERATING PROFIT

The operating profit is stated after charging:

Period
1.10.22
Year Ended to
31.3.25 31.3.24
£    £   
Depreciation - owned assets 124,861 160,504
Development costs amortisation 10,960 39,630

5. INTEREST PAYABLE AND SIMILAR EXPENSES
Period
1.10.22
Year Ended to
31.3.25 31.3.24
£    £   
Interest payable 21,823 2,064
Hire purchase - 1,178
21,823 3,242

6. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
Period
1.10.22
Year Ended to
31.3.25 31.3.24
£    £   
Current tax:
UK corporation tax 45,229 118,812

Deferred tax (7,474 ) 8,596
Tax on profit 37,755 127,408

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


7. DIVIDENDS
Period
1.10.22
Year Ended to
31.3.25 31.3.24
£    £   
Final 500,000 250,000

8. INTANGIBLE FIXED ASSETS
Development
Goodwill costs Totals
£    £    £   
COST
At 1 April 2024
and 31 March 2025 2,567,884 114,680 2,682,564
AMORTISATION
At 1 April 2024 2,567,884 103,720 2,671,604
Amortisation for year - 10,960 10,960
At 31 March 2025 2,567,884 114,680 2,682,564
NET BOOK VALUE
At 31 March 2025 - - -
At 31 March 2024 - 10,960 10,960

9. PROPERTY, PLANT AND EQUIPMENT
Improvements Fixtures
Short to and
leasehold property fittings
£    £    £   
COST
At 1 April 2024 638,900 298,056 512,550
Additions 16,657 505,830 12,060
At 31 March 2025 655,557 803,886 524,610
DEPRECIATION
At 1 April 2024 471,370 88,485 473,455
Charge for year 23,500 64,210 9,598
At 31 March 2025 494,870 152,695 483,053
NET BOOK VALUE
At 31 March 2025 160,687 651,191 41,557
At 31 March 2024 167,530 209,571 39,095

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


9. PROPERTY, PLANT AND EQUIPMENT - continued

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 April 2024 48,624 225,610 1,723,740
Additions 36,445 1,289 572,281
At 31 March 2025 85,069 226,899 2,296,021
DEPRECIATION
At 1 April 2024 37,723 202,304 1,273,337
Charge for year 11,836 15,717 124,861
At 31 March 2025 49,559 218,021 1,398,198
NET BOOK VALUE
At 31 March 2025 35,510 8,878 897,823
At 31 March 2024 10,901 23,306 450,403

10. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 April 2024
and 31 March 2025 1,000
NET BOOK VALUE
At 31 March 2025 1,000
At 31 March 2024 1,000

The company's investments at the Statement of Financial Position date in the share capital of companies include the following:

One Pharmacy Ltd
Registered office:
Nature of business: Pharmacy
%
Class of shares: holding
Ordinary 100.00
31.3.25 31.3.24
£    £   
Aggregate capital and reserves (136,803 ) (158,133 )
Profit/(loss) for the year/period 21,330 (59,226 )

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


11. INVENTORIES
31.3.25 31.3.24
£    £   
Finished goods 799,417 625,755

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.25 31.3.24
£    £   
Trade debtors 10,314 10,306
NHS debtors 518,870 521,697
Amounts owed by group undertakings 414,343 570,541
Other debtors 1,371,299 1,346,288
VAT 170,586 171,457
Prepayments and accrued income 20,246 35,290
2,505,658 2,655,579

The rental deposits included within Other Debtors £13,130 (2024: £13,130) are secured on the company's freehold property.

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.25 31.3.24
£    £   
Hire purchase contracts (see note 15) 24,947 24,983
Trade creditors 1,076,844 1,137,561
Amounts owed to group undertakings 972,307 -
Tax 49,152 118,812
Social security and other taxes 26,510 20,708
Other creditors 3,552 3,305
Accrued expenses 25,832 16,514
2,179,144 1,321,883

14. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.3.25 31.3.24
£    £   
Hire purchase contracts (see note 15) 16,632 41,639

15. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase
contracts
31.3.25 31.3.24
£    £   
Net obligations repayable:
Within one year 24,947 24,983
Between one and five years 16,632 41,639
41,579 66,622

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


15. LEASING AGREEMENTS - continued

Non-cancellable
operating leases
31.3.25 31.3.24
£    £   
Within one year 83,687 -
Between one and five years 353,072 -
In more than five years 375,120 -
811,879 -

After the year-end no new leases have been signed because current leases have no expiry, within one year and most of the leases will be valid for at least next fourteen years.

16. PROVISIONS FOR LIABILITIES
31.3.25 31.3.24
£    £   
Deferred tax 17,758 25,232

Deferred
tax
£   
Balance at 1 April 2024 25,232
Utilised during year (7,474 )
Accelerated capital allowances
Revaluation gains
Balance at 31 March 2025 17,758

17. CALLED UP SHARE CAPITAL

Allotted and issued:
Number: Class: Nominal 31.3.25 31.3.24
value: £    £   
2,000 Share capital 1 o1 2,000 2,000

18. RESERVES
Retained
earnings
£   

At 1 April 2024 2,569,073
Profit for the year 94,311
Dividends (500,000 )
At 31 March 2025 2,163,384

HYPERCHEM LIMITED (REGISTERED NUMBER: 01818053)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


19. RELATED PARTY DISCLOSURES

At the year-end, company has following related parties transactions to report:

Related PartiesRelationshipTransactions and Balances
One Pharmacy Ltd100% SubsidiaryOwed an amount of £414,343 (2024: £384,343)


The Doctors
Method Ltd
Company incorporated in
England and Wales, Fully
owned by directors'
daughter Anika Patel



Owed an amount of £1,294,308 (2024: £1,267,613



)


Avas holdings
Parent company, 100%
Ownership of Hyperchem
Ltd

Hyperchem Ltd, owed them an amount of last year it was
due from them £972,307 (£186,198


)

S Patel, H Patel, H
Patel, A Patel

Family member of the
directors'
They were on company's payroll but their wages were on
commercial terms and fully disclosed into the accounts and
all employment taxes have been paid to the HMRC.
S Patel, V PatelDirectorsMinimum director's remuneration




Sava Property Ltd


Another subsidiary of Avas
Holdings Ltd (Group
company




)
No balance but it charged rents of £70,000f or premises
occupied by the Hyperchem Limited to carried out its
trading activities. it has also took out a loan of £900,000
for Hyperchem Limited, which has been owed back to
Sava Property Limited via Avas Holdings Limited


20. ULTIMATE CONTROLLING PARTY

At the balance sheet date, AVAS HOLDINGS LIMITED, was considered to be the ultimate controlling party due to its 100% shareholding of the company.